Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$9.36 -3.1%	$9.96	$6.02 ▼ $11.31	$2.02B	1.11	3.04 million shs	7.45 million shs
FOLD Amicus Therapeutics	$5.93 +4.2%	$6.28	$5.51 ▼ $12.65	$1.75B	0.54	3.13 million shs	9.95 million shs
LGND Ligand Pharmaceuticals	$114.15 -1.3%	$107.71	$81.74 ▼ $129.90	$2.23B	0.83	119,005 shs	327,870 shs
OSIR Osiris Therapeutics	$18.99	$18.99	$7.01 ▼ $19.30	$655.69M	N/A	205,753 shs	N/A

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	-3.11%	-7.33%	-11.36%	+19.08%	+51.46%
FOLD Amicus Therapeutics	+4.22%	+5.14%	-2.79%	-29.66%	-38.87%
LGND Ligand Pharmaceuticals	-1.33%	+0.07%	+13.93%	+6.07%	+46.68%
OSIR Osiris Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCRX BioCryst Pharmaceuticals	4.4454 of 5 stars	4.4	2.0	0.0	4.2	2.0	1.7	0.6
FOLD Amicus Therapeutics	3.9215 of 5 stars	3.4	1.0	0.0	4.3	2.0	0.0	1.9
LGND Ligand Pharmaceuticals	4.7367 of 5 stars	3.5	3.0	0.0	4.4	2.2	3.3	1.9
OSIR Osiris Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCRX BioCryst Pharmaceuticals	2.89	Moderate Buy	$16.56	76.88% Upside
FOLD Amicus Therapeutics	2.70	Moderate Buy	$16.22	173.56% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$146.14	28.03% Upside
OSIR Osiris Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest OSIR, LGND, BCRX, and FOLD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
5/9/2025	LGND Ligand Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$142.00 ➝ $145.00
5/7/2025	BCRX BioCryst Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $11.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $17.00
5/6/2025	BCRX BioCryst Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/2/2025	FOLD Amicus Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $22.00
5/2/2025	FOLD Amicus Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$12.00 ➝ $9.00
4/29/2025	BCRX BioCryst Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$20.00
4/11/2025	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $11.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCRX BioCryst Pharmaceuticals	$450.71M	4.35	N/A	N/A	($2.30) per share	-4.07
FOLD Amicus Therapeutics	$528.29M	3.46	N/A	N/A	$0.65 per share	9.12
LGND Ligand Pharmaceuticals	$167.13M	13.18	$1.59 per share	72.00	$43.95 per share	2.60
OSIR Osiris Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCRX BioCryst Pharmaceuticals	-$88.88M	-$0.26	N/A	N/A	2.19	-10.62%	N/A	-11.06%	8/4/2025 (Estimated)
FOLD Amicus Therapeutics	-$56.11M	-$0.09	N/A	13.79	N/A	-5.41%	4.67%	1.05%	8/14/2025 (Estimated)
LGND Ligand Pharmaceuticals	-$4.03M	-$7.12	N/A	30.77	N/A	-73.07%	-7.83%	-6.92%	8/5/2025 (Estimated)
OSIR Osiris Therapeutics	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest OSIR, LGND, BCRX, and FOLD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	LGND Ligand Pharmaceuticals	$1.23	$1.33	+$0.10	-$2.21	$37.84 million	$45.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OSIR Osiris Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCRX BioCryst Pharmaceuticals	N/A	2.93	2.88
FOLD Amicus Therapeutics	2.02	3.34	2.47
LGND Ligand Pharmaceuticals	N/A	5.27	5.02
OSIR Osiris Therapeutics	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCRX BioCryst Pharmaceuticals	85.88%
FOLD Amicus Therapeutics	N/A
LGND Ligand Pharmaceuticals	91.28%
OSIR Osiris Therapeutics	0.28%

Insider Ownership

Company	Insider Ownership
BCRX BioCryst Pharmaceuticals	4.80%
FOLD Amicus Therapeutics	2.20%
LGND Ligand Pharmaceuticals	7.00%
OSIR Osiris Therapeutics	43.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCRX BioCryst Pharmaceuticals	530	209.25 million	199.21 million	Optionable
FOLD Amicus Therapeutics	480	307.93 million	301.16 million	Optionable
LGND Ligand Pharmaceuticals	80	19.29 million	17.94 million	Optionable
OSIR Osiris Therapeutics	342	34.53 million	N/A	Not Optionable

OSIR, LGND, BCRX, and FOLD Headlines

Recent News About These Companies

Ryoncil, the first FDA-approved mesenchymal stromal cell therapy

March 3, 2025 | finance.yahoo.com

Global Medical Disposables Market to be worth USD 326.4 Billion by 2033, Reveals Future Market Insights

December 18, 2024 | fmiblog.comF

Human Osteoblasts Market Projected to Reach USD 85.3 Million by 2034 at a 6.4% of CAGR

October 31, 2024 | fmiblog.comF

Global Medical Disposables Market to Reach USD 326…

October 24, 2024 | pharmiweb.comP

Global Regenerative Medicine Market to Reach $472.95 Billion by 2032 | 25.86% CAGR

October 3, 2024 | taiwannews.com.twT

Wound Care Biologics Market Future Looks Bright for Market Size with Soaring Projections

September 23, 2024 | taiwannews.com.twT

Smith & Nephew buys Osiris in regenerative medicine push

July 25, 2024 | pharmaphorum.comP

Type 1 Diabetes Drugs Market Revenue, Price, Growth Rate, Forecast To 2032

July 19, 2024 | taiwannews.com.twT

Active Wound Care Market to Grow at 5.5% CAGR Through 2032 Amid Rising Chronic Wound Cases

May 29, 2024 | pharmiweb.comP

Global Topical Wound Agents Market Size To Exceed USD 3.7 Billion By 2033 | CAGR Of 6.89%

May 25, 2024 | finance.yahoo.com

Cell and Gene Therapy Market Power of Anticipation Preparing for the Future of Market Size

May 2, 2024 | taiwannews.com.twT

Tissue Engineering and Regeneration Market [2028]: Navigating Opportunities and Challenges

April 24, 2024 | informazione.itI

Knee Cartilage Repair Market Growth Analysis, Size, Prominent Players, Overview, and Forecast 2024 to 2032

April 19, 2024 | taiwannews.com.twT

Knee Cartilage Repair Market Size, Share, Growth Statistics, Latest Trends, and Forecast 2024 to 2032

April 12, 2024 | taiwannews.com.twT

Global Anti-Biofilm Wound Dressing Market Projected to Witness Significant Growth US$ 1939.45 million by 2033

April 8, 2024 | fmiblog.comF

Kanak Kanti

March 19, 2024 | fool.com

Anticipating Growth Trends And Shifts In The Global Meniscus Allograft Market

February 20, 2024 | opprairie.comO

Unlocking Niche Opportunities In Cartilage Allograft Market

February 20, 2024 | opprairie.comO

MIT's Albumin-based cancer vaccine shows promising results in trials

February 18, 2024 | msn.com

Arnold Caplan, biologist who studied cells, dies at 82

February 11, 2024 | cleveland.comC

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSIR, LGND, BCRX, and FOLD Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

$9.36 -0.30 (-3.11%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$9.48 +0.12 (+1.29%)

As of 06/27/2025 07:55 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Amicus Therapeutics NASDAQ:FOLD

$5.93 +0.24 (+4.22%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$5.82 -0.11 (-1.77%)

As of 06/27/2025 07:13 PM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Ligand Pharmaceuticals NASDAQ:LGND

$114.15 -1.54 (-1.33%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$114.10 -0.06 (-0.05%)

As of 06/27/2025 05:18 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Osiris Therapeutics OTCMKTS:OSIR

$18.99 0.00 (0.00%)

As of 04/17/2019

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time